

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

April 8, 2015

Hidrex Gmbh % Stefanie Bankston Official Correspondent 2611 Shark Circle Texas City, TX 77591

Re: K133033 Trade/Device Name: Hidrex PSP1000 Regulation Number: 21 CFR 890.5525 Regulation Name: Iontophoresis Device Regulatory Class: Class III Product Code: EGJ Dated: February 23, 2015 Received: February 27, 2015

Dear Ms. Bankston,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Our substantially equivalent decision does not apply to the drugs that you will label or promote for use with your device. Therefore, you may neither label nor promote your device for use with

specific drugs, nor package drugs with your device prior to FDA having approved the drugs for iontophoretic administration. For information on the requirements for marketing new drugs, you may contact:

Director Division of Drug Labeling Compliance (HFD-310) Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, Maryland 20857

As you are aware, there are concerns relating to the fact that no drug is currently labeled for administration via an iontophoresis device. The Agency currently is evaluating this public health concern regarding the safety and effectiveness of this route of administration of drugs, and in the near future will inform manufacturers of certain additional steps the Agency believes are necessary to address this concern.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<u>http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</u> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Felipe Aguel -S

for Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health

Indications for Use

510(k) Number *(if known)* K133033

Device Name HIDREX PSP1000

Indications for Use (Describe)

This Tap-Water-Iontophoresis device is intended to treat hyperhidrosis (pathological sweating) affecting hands, feet, and underarms. Any other use or usage beyond this scope is considered un-intended use and may have dangerous consequences.

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff *PRAStaff@fda.hhs.gov*

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



K133033

510(k) SUMMARY

July 24, 2014

Office of Device Evaluation U.S. Food & Drug Administration

Dear Madame/Sir;

In accordance with Section 510(k) of the Federal Food & Drug and Cosmetic Act, and in conformance with 21 CFR Part 807, pre-market notification is hereby made of the intention of HIDREX GmbH to introduce into interstate commerce for commercial distribution the iontophoresis device HIDREX PSP1000.

Applicant: HIDREX GmbH Otto-Hahn-Str. 12 D-42579 Heiligenhaus Phone_: +49 (0)2056 98 11 0 Fax +49 (0)2056 98 11 31 Email: info@hidrex.de Info@hidrex.de

User fee Organization Number: 348050

Contact Person:	Mr. Andreas Kaemper Phone: +49 (0)2056 98 11 0 Email: <u>kaemper@hidrex.de</u>
US-agent:	Mrs. Stefanie D. Bankston BEO MedConsulting Berlin GmbH 3001 Ferndale Dr League City TX 77573 Phone: 713-483 46 17 Email: <u>s.bankston@beoberlin.com</u>

Device:

- a. Proprietary: HIDREX PSP1000
- b. Common Name: Iontophoresis device, Other uses
- c. Regulation description: Iontophoresis device
- d. Device Class: III
- e. Regulation Number: 890.5525
- f. Review Panel: Physical Medicine
- g. Product Code: EGJ

Predicate Device Information:

We claim substantial equivalence for the subject device in intended use, design and function to the predicate device MD-1A (K964208) by R.A. Fischer CO. CORP and to the predicate device Drionic (K831320) by General Medical Company.

Intended Use / Indication for Use:



This Tap-Water-Iontophoresis device is intended to treat hyperhidrosis (pathological sweating) affecting hands, feet and underarms.

Any other use or usage beyond this scope is considered un-intended use and may have dangerous consequences.

Scientific Concept:

lontophoresis is a physical process in which ions flow diffusively in a medium driven by an electric field. Iontophoresis is to be distinguished from the carriage of uncharged molecules by diffusive fluxes of other molecules, especially of solvent molecules.

In the treatment of hyperhidrosis, tap water is often the chosen solution for mild and medium forms.

Since 1968, tap water iontophoresis has been employed as the method of choice for treating palmoplantar hyperhidrosis. Special electrodes also allow treatment of axillary hyperhidrosis. Tap water iontophoresis also can extend symptom -free intervals in dyshidrotic palmar eczema. The mechanism action is most likely a functional disturbance of the secretory mechanism of eccrine acini. During the induction phase, treatments are carried out once daily. Current direction may be switched before each treatment or, even better, kept constant until one side, preferably the dominant hand on the anode, is sweating normally. Then polarity is switched until both hands are adequately treated. During the weekly maintenance therapy, current direction is switched before each treatment. The most comfortable means of iontophoretic treatment employs pulsed direct current of high frequency (5-10 kHz) which is better tolerated than continuous direct current. Side effects are minimal and transient. Only slight skin irritation or sensations of discomfort may occur during treatment. Electric burns and shocks can be avoided by following routine precautions. Contraindications for tap water iontophoresis are metallic implants, such as cardiac pacemakers, or orthopaedic joint or bone implants, if they are within the electric circuit.

Device Description:

HIDREX iontophoresis devices are primarily intended for treating hyperhidrosis1 (excessive sweating) of hands and/or feet. Provided the optional axillary applicators are utilized, the system can also be used for treating axillary hyperhidrosis.

Control unit:	
The control unit is connected with the	
power supply/safety wall adapter. The	
unit includes all connection-jackets to	K 🖾 🙈 🏠
attach the accessories for the	
treatment. It includes the control-	
buttons to choose the therapy-mode.	
Dimension: 190 x 137 x 49 mm	
Power supply / safety wall adapter	
that is connected with the control unit	Coner 1
(secondary plug). The primary plug is	
connected to the AC-socket in the	
wall.	
	7









Control unit







1 Display	Main Display to show therapeutic settings	
2 Button	Adjustment to lower the dose	
3 Button	Adjustment to raise the dose	
4 Button	Adjustment to decrease the therapeutic time-span	
5 Button	n Adjustment to increase the therapeutic time-span	
6 LED-Indicator 3 Indicators to show user settings / application mode		
7 LED Indicator	7 LED Indicator 1 Indicator to show therapeutic mode activated: current	
8 LED Indicator	1 Indicator to show therapeutic mode activated: pulsed current	
9 LED Indicator 1 Indicator to show 'ready for treatment' (electric circuit closed)		

Current Density of Applicators and Electrodes

Applicator	Conductive Area [sqin]	Max.Density at 30mA [mA/sqin]	PeakDensity at 35mA [mA/sqin]
Hand-Feet, Hard Shell Case individual Water Surface	112.13	0.26	0.31
Hand-Feet, Ergonomic Tray individual Water Surface	90.88	0.33	0.38
Hand-Feet, individual Electrode	122.13	0.24	0.28
Hand-Feet, individual Cover Towel	98.8	0.30	0.35
Axillary, Sponge Cushions	36.75	0.81	0.95
Axillary, individual Electrode	8.25	3.63	4.24



Function:

The HIDREX treatment concept comprises two treatment phases:

<u>Phase 1:</u> The initial phase (therapy initiation) is conducted under a doctor's supervision with the doctor's or the patient's device. During this stage, patients learn to administer treatments. For therapy initiation, three weekly treatments of approximately 15 minutes each should be scheduled (not more than one treatment per day). Sweat secretion will normalize after approximately 10 treatments.

<u>Phase 2:</u> Long term treatment (maintenance therapy) is necessary because the HIDREX treatment effect is reversible. Patients should conduct maintenance therapy sessions by themselves at home and with their own unit. Depending on the severity of the condition, maintenance therapy involves one to three weekly sessions of approximately 15 minutes each.

The Hidrex PSP1000 with changeable pulse-width allows the innovative adjustment of the pulse-intensity.

Extensive trials showed that the efficiency of pulsed current could be increased dramatically. The effectiveness is not reduced at all compared to direct current when the pulse-width is 90%. The possible pulse-widths are 50%, 60%,70%, 80%, 90% and 100%

Application:



feet

hands

Performance data:

DC current output	max. 60 V
(automatically	max. 35 mA
regulated)	
Pulsed current	max. 60 V
output	max. 35 mA
(automatically	9.9 kHz
regulated)	



Comparison to legally marketed device MD-1A (K964208) by R.A. Fischer CO. CORP (Substantial Equivalence):

The Chart below summarizes the similarities and differences:			
	DEVICE	SE-DEVICE	
	HIDREX PSP1000	MD-1A (k964208)	
Indication for use	This Tap-Water-Iontophoresis	The MD-1a / MD-2 Galvanic units	
	device is intended to treat	are indicated for use in the treatment	
	hyperhidrosis (pathological	of palmar or plantar hyperhidrosis	
	sweating) affecting hands, feet and	(abnormal sweating not related to	
	underarms.	exercise or resulting from another	
		underlying condition) using the	
		technique of tapwater iontophoresis.	
Performance			
DC current output	max. 60 V	data not available	
	max. 35 mA	0-10 and 0-50 mA	
	max. 60 V		
Pulsed current	max. 35 mA		
	9.9 kHz		
υτραί	5 output modes (pulse-width: 50% 60% 70% 80% and 90%)		
Polarity reversal (to			
alternate POS and	manual	manual	
NEG application)	mandai	manadi	
Automatic current			
regulation	Yes	Only over-current protection	
Timer	Yes		
	LCD-multi character display to		
Display	display all session settings		
Microprocessor			
controlled with built-	Yes		
in self-test			
Controls			
Meter	digital Monitor	analog meter	
Intensity	soft sensor buttons	analog switch/knob	
Output Jacks	6mm insulated connectors	6mm insulated connectors	
Application-accessory			
Feet	plastic case with towel inside	plastic tray / case with towel inside	
Hands	plastic tray / case with towel inside	plastic tray / case with towel inside	
Axillary applicators	Pads		
Dimensions			
Control unit	7,5" (W) x 2" (H) 5,4" (D)	10" (W) x 4" (H) 12" (D)	
	Approximately 1 lb	Approximately 5 lb	
Hard-shell-case	13.4" x10.8" x 3.3"	data not available	
Treatment tray	10.2" x 15.75" x 2.2"	data not available	
Axillary sponge	2.9" x 3.45" x 1.3"	data not available	
cushions			
Towel	8.1" x 12.2"	data not available	
Electrodes (feet,	4.5" x 11.2" x 2.4"	data not available	
hands)			
Electrodes	1.9" x 2.17" x 0.6"	data not available	
(underarms)			
Conductive area [sqin]			

The Chart below summarizes the similarities and differences:

HDRFX	MED
	VET
	AHAN

Hard shell Case	112.13	data not available	
Treatment tray	90.88	data not available	
Towel	98.8	data not available	
Sponge Cushion	36.75	data not available	
Electrode (feet, hands)	122.13	data not available	
Electrode (underarms)	8.25	data not available	
Density at 30mA [mA/sqin]			
Hard shell Case	0.26	data not available	
Treatment tray	0.33	data not available	
Towel	0.30	data not available	
Sponge Cushion	0.81	data not available	
Electrode (feet, hands)	0.24	data not available	
Electrode (underarms)	3.63	data not available	
Stimulating device			
Signal type	Monophasis square, at DC: pulsed square signal, selectable in increments of 10 from 50% to 100%	data not available	
Leakage current Type BF	Patient leakage current AC: +000.9 µA Patient leakage current AC SFC: +000.4 µA Patient leakage current DC: +000.0 µA Patient leakage current NAT: +004.2 µA	data not available	
Energy output to patient	treatment time: 10 Minutes W = 9.8 V * 0,0008 A * 600 s = 4,704 Ws treatment time: 15 Minutes W = 9.8 V * 0,0008 A * 900 s = 7,056 Ws 1 min => 0,47 Ws = 0,47 J	data not available	
Power supply			
	external	internal	
	100-240 V~ / 50-60 Hz	100-240 V~ / 50-60 Hz	
input	400mA	data not available	
	12 V=		
output	max. 500mA		
	6 VA		
Certification			
CE	YES	NO	
Standards		-	
	IEC 60601-1:2007	?	

Difference's Analysis <u>These technical differences were identified:</u>

	Subject device (sd)	Predicate device (pd)
1.	DC-current output max. 35mA	DC-current output 0-10 and 0-50mA



	The pd has two output ranges because it uses an analog Ampere-meter. It is very likely to make reading-mistakes using a wide-range-scale while operating in a low-current mode. Therefore, the manufacturer suggests to use the low-range-scale (0-10mA), while using the device in the low-current-mode. However, it is still likely to make mistakes. The sd has a display that shows digital digits. No matter what the current-mode is, it		
	is unlikely to make reading-mistakes. There scale-ranges.	efore there is no need to have separated	
2.	DC and pulsed-current output	Only DC-current output	
	A pulse-width of 100% (no pause) is corresponding to the classical DC method. However, pulse-width-method makes the sensation for the user more present because of the physiological 10kHz frequency. The pulsed current output modes are more sensitive. So the risk of skin-irritation is reduced.		
3.	Automatic current regulation and over- current protection	Over-current protection	
	The pd, due to its basic concept with analog technology, has a manual current adjustment. The patient/user has to read continuously the analog meter to stay with the appreciated settings. The sd has a microprocessor that is able to watch physical conditions. The sd can automatically adjust the current and keep the therapeutic settings based on the patient's settings. Physical changes caused by the patient, like position or movements, can automatically be compensated		
4.	Timer		
	The pd has no timer. The patient has to measure and check the time span for the treatment-session by himself. The sd has a timer that automatically starts the countdown when the treatment starts. The patient's benefit is the automatic ending of the treatment session. The risk for an overdose is reduced.		
5.	Display	Analog meter	
	The pd has an analog Ampere-meter. It is very likely to make reading-mistakes using a wide-range-scale while operating in a low-current mode. It is also necessary to have god visibility to be able to read the relatively small numbers on the meter. Reading mistakes are likely.The sd has a display with big digital digits. The display shows the setting as well as the current. The possibility to make reading mistakes is unlikely.		
6.	microprocessor	Analog technology	
	The pd operates based on analog technology. The sd operates based on digital technology. The advantage is to be able to check and control the treatment-parameter during the session, to reduce the weight of the device and offer more adjustment for treatment-parameter.		
7.	Digital Monitor	Analog meter	
	The pd has an analog Ampere-meter. It is very likely to make reading-mistakes using a wide-range-scale while operating in a low-current mode. It is also necessary to have god visibility to be able to read the relatively small numbers on the meter. Reading mistakes are likely.		



	The sd has a display with big digital digits. The display shows the setting as well as the current. The possibility to make reading mistakes is unlikely.		
8.	Soft sensor buttons	Analog switch/knob	
	Analog switches and knobs are subject to corrosion. It is likely that their precision and even functionality is reduced after a few years of use. The sd has foil-insulated micro-switches. They last much longer and it is unlikely that they loose their functionality at all.		
9.	Application accessory axillary-sponge	No axillary-sponge	
	Some patients suffer also from axillary hyperhidrosis. To offer effective treatment also for these patients the sd has specialized accessory.		
10.	External power supply	Internal Power supply	
	The pd has an internal power supply while the sd has an external power supply. There are no significant differences concerning safety or comfort. A break in the power supply can be fixed more easily with an external one.		

The above mentioned differences between the subject device and the predicate device are due to technological progress. The subject device and its modern technology increase the comfort and benefit for the patient in using the device. Misuse or misunderstanding by using an analog meter is impossible with the clear digital-display of the subject device. All settings are protocolled and displayed in the display. This avoids mistakes in the user-setting. The additional benefit of the pulsed-current is demonstrated in several clinical trials. The safety of the device was demonstrated in non-clinical tests according to recognized standards.

Comparison between materials and principles of use

The HIDREX PSP1000 as well as the predicate device MD-1A GALVANIC UNIT by R.A. Fischer Co. (K964208) use a standard housing made from ABS-Plastic. This housing material is non-toxic and used with many other devices. The same is true for the trays/cases that are used to apply the therapy. None of these materials is in direct contact with the skin for medical purpose. Both devices, the subject device as well as the predicate device, use standard-household-towels that are in direct contact with the patients skin.

The system components are the same. Both systems consist of a central-unit and application components. The subject device has in addition to the foot- and hand-applicator also an axillary applicator. Therefore the subject device offers more benefit to the user than the predicate device.

The principles of use are basically the same. The subject device uses a modern technology like LCD-display to display the setting etc., micro-buttons to adjust and digital controlled processes, while the predicate device has analog technology, like an analog meter to display the current, analog resistor-knob for adjustments and no digital control. Therefore the subject device offers higher comfort and control and advanced usability.

The performance of the subject device and the predicate device are similar concerning the standard dc-current-therapy. The subject device offers a pulsed current in addition, which makes the sensation for the user more present because of the physiological 10kHz frequency.



In conclusion the differences between the subject device and the predicate device don't lead to any harm of the patient or third persons. Comfort and usability is increased with the subject device compared to the predicate device.

Comparison to legally marketed device Drionic (K831320) by General Medical Company (Substantial Equivalence):

	DEVICE HIDREX PSP1000	SE-DEVICE Drionic (k831320)			
Indication for use	This Tap-Water-Iontophoresis	The Drionic device is indicated for			
	device is intended to treat	use in the treatment of hyperhidrosis			
	hyperhidrosis (pathological	(abnormal sweating) affecting			
	sweating) affecting hands feet and	hands feet and underarms. It uses			
	underarms	the technique of tap water			
		iontophoresis.			
Performance					
	max. 60 V	hand or feet treatment: 9V			
		underarm treatment: 18V			
DC current output	max. 35 mA	hand or feet treatment: 6-14mA			
		underarm treatment: 1-2,5mA			
	max. 60 V				
Dulaad ourrent	max. 35 mA				
Puisea current	9.9 kHz				
ouipui	5 output modes (pulse-width: 50%,				
	60%, 70%, 80% and 90%)				
Polarity reversal					
(to alternate POS	monual	No			
and NEG	manuai	INO			
application)					
Automatic current	Voc	No			
regulation	165	110			
Timer	Yes	No			
Display	display all session settings	No			
Microprocessor					
controlled with	Yes	No			
built-in self-test					
Controls					
Motor	digital Monitor	No			
	soft sensor buttons	analog control wheel			
Output Jacks	6mm insulated connectors	No			
Application-					
accessory					
Feet	plastic tray / case with towel inside	data not available			
Hands	plastic tray / case with towel inside	data not available			
Axillary applicators	Pads	data not available			
Dimensions					
size	Control unit:	hand or feet unit:			
	7,5" (W) x 2" (H) 5,4" (D)	11,6" (W) x 2,2" (H) 4,9" (D)			
		underarm unit:			
		4,4" (W) x 0,6" (H) 4,3" (D)			
weight	Approximately 1 lb	0,825 lb or 0,374 lb			
Hard-shell-case	13.4" x10.8" x 3.3"	data not available			

The Chart below summarizes the similarities and differences:



Treatment trav	10 2" x 15 75" x 2 2"	data not available
Axillary sponge	2 9" x 3 45" x 1 3"	data not available
cushions	2.0 X 0.40 X 1.0	
	8 1" x 12 2"	data not available
Electrodes (feet	1 5" x 11 2" x 2 4"	data not available
banda)	4.5 X 11.2 X 2.4	
	4.0" × 0.47" × 0.0"	dete net eveileble
	1.9 X 2.17 X 0.6	data not available
(underarms)		
Conductive area		
[sqin]		
Hard shell Case	112.13	data not available
Treatment tray	90.88	data not available
Towel	98.8	data not available
Sponge Cushion	36.75	data not available
Electrode (feet.	122.13	data not available
hands)		
Electrode	8 25	data not available
(underarms)	0.20	
(dildorarino)		
Density at 30mA		
[ma/sain]		
	0.26	data not available
	0.20	
	0.33	
	0.30	
Sponge Cushion	0.81	data not available
Electrode (feet,	0.24	data not available
hands)		
Electrode	3.63	data not available
(underarms)		
Stimulating device		
Signal type	Monophasis square, at DC: pulsed	data not available
	square signal, selectable in	
	increments of 10 from 50% to 100%	
Leakage current	Patient leakage current AC: +000.9	data not available
Type BF	μA	
51	Patient leakage current AC SFC:	
	+000.4 µA	
	Patient leakage current DC: +000.0	
	μA	
	Patient leakage current NAT: +004.2	
	чA	
Energy output to	treatment time: 10 Minutes	data not available
patient	W = 9.8 V * 0.0008 A * 600 s =	
	4.704 Ws	
	treatment time: 15 Minutes	
	W = 9.8 V * 0.0008 A * 900 s =	
	7 056 Ws	
	1 min = > 0.47 Ws = 0.47 J	
Power supply		
	external	internal
		hand or foot trootmont: 0\/
Input	100-240 V~/ 30-00 HZ	underer treatment 19/
input	400	
autro et	400IIIA	
output	12 V=	nand of feet treatment: 9V



		underarm treatment: 18V	
	max. 500mA		
	6 VA		
Certification			
CE	YES	NO	
Standards	IEC 60601-1:2007	No Standards	
GMP	Yes	data not available	

Comparison between principles of use

The HIDREX PSP1000 has nearly the same system components as the predicate device Drionic by General Medical Company (K831320). Both systems consist of a unit for hand and foot treatment and an application component for underarm treatment.

The principles of use are basically the same. The subject device uses a modern technology like LCD-display to display the setting etc., micro-buttons to adjust and digital controlled processes, while the predicate device has old technology like an analog control wheel to adjust the intensity, a light to display the operating state and no digital control. Therefore the subject device offers higher comfort and control and an advanced usability.

The performance of the subject device and the predicate device are the same concerning the standard dc-current-therapy. In addition the subject device offers a pulsed current which makes the sensation for the user more present because of the physiological 10kHz frequency.

Difference's Analysis

These technical differences were identified:

	Subject device (sd)	Predicate device (pd)		
1.	DC-current output max. 35mA	DC-current output 6-14mA and 1-2,5mA		
	The pd has two output ranges because it has no Ampere-meter. The sd has a display that shows digital digits. No matter what the current-mode is, it is unlikely to make reading-mistakes. Therefore there is no need to have separated scale-ranges.			
2.	DC and pulsed-current output	Only DC-current output		
	A pulse-width of 100% (no pause) is corresponding to the classical DC method. However, pulse-width-method makes the sensation for the user more present because of the physiological 10kHz frequency. The pulsed current output modes are more sensitive. So the risk of skin-irritation is reduced.			
3.	Polarity reversal (to alternate POS and NEG application)			
	The pd has no possibility to change the polarity. The sd provides a manual adjustable reversible polarity. The user is able to change between positive and negative application.			
4.	Automatic current regulation and over- current protection	No automatic regulation or protection		
	The pd has a manual adjustment. The patient/user has to advance the control wheel until there is a comfortable tingle. During the treatment-session the patient/ user is responsible for the intensity by himself without any technical help.			



	The sd has a microprocessor that is able to watch physical conditions. The sd can automatically adjust the current and keep the therapeutic settings based on the					
	patient's settings. Physical changes caused by the patient, like position o	patient's settings. Physical changes caused by the patient, like position or				
	movements, can automatically be compensated. This reduces the risk of	movements, can automatically be compensated. This reduces the risk of a harmful				
	high intensity.	high intensity.				
5.	. Timer					
	The pd has no timer. The patient has to measure and check the time spa	n for the				
	treatment-session by himself.					
	The sd has a timer that automatically starts the countdown when the trea	tment				
	starts. The patient's benefit is the automatic ending of the treatment sess	ion. The risk				
	for an overdose is reduced.					
6.	. Display					
	The pd has no display or any other possibility to check setting and curren	it.				
	The eddee e display with his disited disite. The display shows the estimates well as					
	the current. The possibility to make reading mistakes is unlikely	as well as				
	the current. The possibility to make reading mistakes is unlikely.					
7.	Microprocessor Analog technology					
	The pd operates based on analog technology.					
	The sd operates based on digital technology. The advantage is to be able	e to check				
	and control the treatment-parameter during the session, to reduce the we	eight of the				
	device and offer more adjustment for treatment-parameter.	-				
8.	. Digital Monitor					
	The pd has no digital monitor.					
	The solution has a display with big digital digits. The display shows the setting	as well as				
	the current. The possibility to make reading mistakes is unlikely.					
a	Soft sensor buttons					
5.	Analog switches and knobs are subject to corrosion. It is likely that their r	recision				
	and even functionality is reduced after a few years of use					
	The sd has foil-insulated micro-switches. They last much longer and it is	unlikely that				
	they loose their functionality at all.					
10.	0. External power supply Internal Power supply					
	The pd has an internal power supply while the sd has an external power	supply.				
	There are no significant differences concerning safety or comfort. A break in the					
	power supply can be fixed more easily with an external one.					
1						

The above mentioned differences between the subject device and the predicate device are due to technological progress. The subject device and its modern technology increases the comfort and benefit for the patient in using the device. Because of the automatic current regulation and protection the risk of a harmful high intensity and of an overdose is reduced. All settings are protocolled and displayed in the display. This avoids mistakes in the user-setting. The additional benefit of the pulsed-current is demonstrated in several clinical trials. The attached trial is an explanation as to why the higher levels of voltage and current do not affect safety and effectiveness of the subject device. Furthermore, the safety of the device was demonstrated in non-clinical tests according to recognized standards.



In conclusion the differences between the subject device and the predicate device don't lead to any harm of the patient or third persons. Comfort and usability is increased with the subject device compared to the predicate device.

Non-clinical tests:

To demonstrate substantial equivalence we performed non-clinical tests according recognized standards:

- To demonstrate electrical safety, software-validation and performance, non-clinical tests were performed according to IEC 60601-1 Medical electrical equipment -General requirements for safety
- To demonstrate safety of the software, non-clinical validation was performed according to IEC 60601-1 Medical electrical equipment - General requirements for safety -- clause 14 Programmable electrical medical systems
- To demonstrate electromagnetic compatibility, non-clinical tests were performed according to IEC 60601-1-2 Medical electrical equipment Part 1-2: General requirements for basic safety and essential performance Collateral standard: Electromagnetic compatibility Requirements and tests.

Quality Assurance and Manufacturing Controls:

HIDREX GmbH operates to an established and certified quality management system according to ISO 13485 requirements.

Conclusion:

The subject device HIDREX PSP1000 is as safe, as effective and performs more comfortable than the predicate devices.